Clinical Trial Update: Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) [Phase 2]

View source ↗

Summary

Phase 2 study of ALXN2050 in proliferative lupus nephritis and IgA nephropathy was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy
• Lupus Nephritis

Drugs mentioned

• ALXN2050

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 2 | Status: TERMINATED | Results posted: 2025-10-15